Observational cohort study to determine the degree and causes of variation in the rate of surgery or primary endocrine therapy in older women with operable breast cancer by Morgan, Jenna L. et al.
Observational cohort study to determine the degree and 
causes of variation in the rate of surgery or primary 
endocrine therapy in older women with operable breast 
cancer
MORGAN, Jenna L., HOLMES, Geoff, WARD, Sue, MARTIN, Charlene, 
BURTON, Maria <http://orcid.org/0000-0002-5411-8181>, WALTERS, 
Stephen J., CHEUNG, Kwok Leung, AUDISIO, Riccardo A., REED, Malcom 
W.R. and WYLD, Lynda
Available from Sheffield Hallam University Research Archive (SHURA) at:
http://shura.shu.ac.uk/27322/
This document is the author deposited version.  You are advised to consult the 
publisher's version if you wish to cite from it.
Published version
MORGAN, Jenna L., HOLMES, Geoff, WARD, Sue, MARTIN, Charlene, BURTON, 
Maria, WALTERS, Stephen J., CHEUNG, Kwok Leung, AUDISIO, Riccardo A., 
REED, Malcom W.R. and WYLD, Lynda (2020). Observational cohort study to 
determine the degree and causes of variation in the rate of surgery or primary 
endocrine therapy in older women with operable breast cancer. European Journal of 
Surgical Oncology. 
Copyright and re-use policy
See http://shura.shu.ac.uk/information.html
Sheffield Hallam University Research Archive
http://shura.shu.ac.uk
lable at ScienceDirect
European Journal of Surgical Oncology xxx (xxxx) xxxContents lists avaiEuropean Journal of Surgical Oncology
journal homepage: www.ejso.comObservational cohort study to determine the degree and causes of
variation in the rate of surgery or primary endocrine therapy in older
women with operable breast cancer
Jenna L. Morgan a, *, Geoff Holmes b, Sue Ward b, Charlene Martin a, Maria Burton c,
Stephen J. Walters d, Kwok Leung Cheung e, Riccardo A. Audisio f, Malcolm WR. Reed g,
Lynda Wyld a, on behalf of the Bridging the Age Gap Trial Management TeamKaren
Collinsh
a Academic Unit of Surgical Oncology, University of Sheffield Medical School, Beech Hill Road, Sheffield, UK
b Department of Health Economics and Decision Science, School for Health and Related Research, University of Sheffield, Sheffield, UK
c Centre for Health and Social Care Research, Sheffield Hallam University, Collegiate Crescent, Sheffield, UK
d Clinical Trials Research Unit, School for Health and Related Research, ScHARR, University of Sheffield, UK
e University of Nottingham, Royal Derby Hospital, Uttoxeter Road, Derby, DE22 3DT, UK
f University of Gothenberg, Sahlgrenska Universitetssjukhuset, 41345, G€oteborg, Sweden
g Brighton and Sussex Medical School, Brighton, UK
h Department of Health and Social care, Sheffield Hallam University, Sheffield, UKa r t i c l e i n f o
Article history:







Treatment variation* Corresponding author. Department of Surgical
University of Sheffield Medical School, Beech Hill Roa
E-mail address: j.morgan@sheffield.ac.uk (J.L. Mor
https://doi.org/10.1016/j.ejso.2020.09.029
0748-7983/© 2020 The Authors. Published by Elsevie
Please cite this article as: J.L. Morgan, G. Holm
rate of surgery or primary endocrine thera
doi.org/10.1016/j.ejso.2020.09.029a b s t r a c t
Background: In the UK there is variation in the treatment of older women with breast cancer, with up to
40% receiving primary endocrine therapy (PET), which is associated with inferior survival. Case mix and
patient choice may explain some variation in practice but clinician preference may also be important.
Methods: A multicentre prospective cohort study of women aged >70 with operable breast cancer. Pa-
tient characteristics (health status, age, tumour characteristics, treatment allocation and decision-making
preference) were analysed to identify whether treatment variation persisted following case-mix
adjustment. Expected case-mix adjusted surgery rates were derived by logistic regression using the
variables age, co-morbidity, tumour stage and grade. Concordance between patients’ preferred and
actual decision-making style was assessed and associations between age, treatment and decision-making
style calculated.
Results: Women (median age 77, range 70e102) were recruited from 56 UK breast units between 2013
and 2018. Of 2854/3369 eligible women with oestrogen receptor positive breast cancer, 2354 were
treated with surgery and 500 with PET. Unadjusted surgery rates varied between hospitals, with 23/56
units falling outside the 95% confidence intervals on funnel plots. Adjusting for case mix reduced, but did
not eliminate, this variation between hospitals (10/56 units had practice outside the 95% confidence
intervals). Patients treated with PET had more patient-centred decisions compared to surgical patients
(42.2% vs 28.4%, p < 0.001).
Conclusions: This study demonstrates variation in treatment selection thresholds for older women with
breast cancer. Health stratified guidelines on thresholds for PET would help reduce variation, although
patient preference should still be respected.
© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Oncology and Metabolism,
d, Sheffield, S10 2JF, UK.
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Older women (>70 years) account for more than a third of new
breast cancer diagnoses in the UK and have poorer outcomes
compared to younger women, with later stage at presentation and
higher rates of non-standard treatment [1e4]. One such treatmentunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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favour of endocrine therapy alone to treat women with oestrogen
receptor positive (ERþ) breast cancer. A Cochrane review
comparing PET with surgery in the over 70s demonstrated superior
rates of local control with surgery but no difference in five year
overall survival rates [5]. However the included studies were
flawed by modern standards as some included women with ER
negative disease and some also included younger, healthy women.
More recent studies have advocated the use of PET only in the very
old or frail [6] and current guidelines state that only patients who
decline surgery or who are unfit for surgery should be treated this
way [7]. In addition, a more recent individual patient meta-analysis
of the randomised trial data, with longer follow-up, conducted by
the Early Breast Cancer Trialist's group, demonstrated significantly
improved long term (15 years) survival in surgically treated women
[8].
Surgery for all older women is not appropriate and may cause
harm if offered to the frailest andmost comorbid older women. This
was recently demonstrated by a study of outcomes of nursing home
residents with breast cancer in the USA [9]. These frail older women
were all treated with surgery which resulted in significant
morbidity and mortality as well as causing significant functional
decline. Surgery may also have a negative impact on quality-of-life
due to long term adverse events such as lymphoedema and chronic
pain. Therefore in frailer older women, for whom life expectancy is
limited, PET is potentially the better option. The issue is deter-
mining where this threshold sits.
In the UK there is considerable variation in the use of PET to treat
women over 70 with operable breast cancer [10], with regional
rates varying between 12 and 40% [11,12]. A study using retro-
spective registry data has shown that case mix (variation in stage,
health, fitness, deprivation levels) does not account for all of this
variation [13]. This suggests that some of this variation is due to
individual surgeon or patient preference. Patient preference for
non-surgical therapy is often reported as a major factor in deter-
mining PET treatment in older patients [14]. However previous
studies examining this have suggested that lower rates of surgery in
older patients are unlikely to be due to patient choice alone [15].
Variation due to surgeon preference is substantial [16].
The treatment of older womenwith operable breast cancer may
be considered a preference-sensitive healthcare decision and so it is
important that shared decision-making be employed, with patients
and healthcare professionals working together to determine the
best treatment for that individual based on the clinical evidence
and the patients’ informed preferences [17,18]. However, there is
some evidence to suggest that not all older patients wish to engage
in shared decision-making, preferring instead to simply receive
information [19] and accept a doctor-led treatment decision
[20e22].
The present study used prospectively collected detailed data
from a large, multi-centre cohort study, which examined surgical
treatment rates across UK hospitals in older women with operable,
ER þ breast cancer (before and after adjustment for case-mix). We
also investigated associations between treatment choice (surgery
or PET) and patient decision-making style to determine whether




Ethics approval and research governance approval was obtained
(IRAS: 12 LO 1808). All patients gave written informed consent or
consent was given by a proxy if the patient was cognitively2
impaired. The trial reporting followed the STROBE guidelines for
reporting of observational studies [23].
Study design
A prospective, multicentre, comprehensive observational cohort
study.
Sites
Patients were recruited from 56 breast units in England and
Wales (Supplemental Table ST1).
Inclusion criteria
Female patients 70 years of age. Primary operable invasive
breast cancer (TNM stages: T1-4, N0-2, M0).
Exclusion criteria
Disease unsuitable for surgery. Previous breast cancer within
five years.
Baseline data collection
Women were recruited at the time of breast cancer diagnosis
and before treatment.
A baseline comprehensive geriatric assessment was performed
using a range of validated tools with data collected on age,
comorbidities (Charlson comorbidity index; CCI) [24], functional
status (activities of daily living; ADL [25] and instrumental activ-
ities of daily living; IADL [26]), cognitive function (using the Mini
Mental State Examination; MMSE [27]). Cognitive impairment was
defined as a MMSE score <24, if they were consented by proxy or if
dementia was identified on the CCI. Nutritional status was
measured using the abridged patient generated subjective global
assessment (aPBSGA) [28].
Baseline tumour characteristics were collected, including
tumour size, biological subtype, grade and nodal status (both
clinical, imaging and pathological status).
Patients’ preferred and actual decision-making styles for their
breast cancer treatment were also recorded using a validated
questionnaire instrument [29,30]. The questionnaire instrument
uses a five point scale for both preferred and actual decision-
making styles, ranging from the doctor making all decisions,
through to the patient making the final decisions (see Supple-
mental Table ST2). The decision-making preferences questionnaire
was applied within 4 weeks of diagnosis and prior to treatment.
Decision-making styles were then classified into one of three cat-
egories: Patient-centred, Shared and Doctor-centred (see Supple-
mental Table ST2).
Statistical analyses
Primary treatment was dichotomised as surgery or PET. The
proportion of patients undergoing surgery was calculated for each
hospital.
Multivariable logistic regression was used to estimate the
probability of a woman undergoing surgical treatment based on
patient level factors, including age, Charlson co-morbidity index,
activities of daily living (ADL), instrumental activities of daily living
(IADL), Eastern Cooperative Oncology Group (ECOG) performance
status, tumour size and grade. Univariate models were first built
including all variables and the model AIC values were used to
determine which variables had most predictive importance.
Fig. 1. Flow diagram for study.
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of importance until the model AIC value ceased to improve. Further
tests adding and removing individual covariates and comparing AIC
led to a preferred model, which explained but did not over-fit the
data. Missing data on disease characteristics and co-morbidity was
handled using the method of multiple imputation by chained
equations (MICE) [31] to produce 25 imputed data sets and
combining the results [32].
Expected rates of surgical treatment were calculated for each
hospital by summing the individual patient probabilities estimated
from the logistic regression model. Risk adjusted rates of surgery
were produced by dividing the observed rate by the expected rate
for each clinician and hospital and multiplying this by the national
rate [33].
Both unadjusted and adjusted rates of surgery at hospital level
were displayed graphically as funnel plots to allow examination of
the variability at each level and identification of outlying practice.
Funnel plots contain two limits; under the hypothesis that treat-
ment choice is randomly determined and independent of clinician
or hospital, 95% of units would be expected to lie within the inner
limits (2 standard deviations from the mean) and 99% within the
outer limits (3 standard deviations from the mean). Hospitals were
said to have a Low Surgery rate if they lay below the 95% CI after
adjustment for case mix and High Surgery rate if they lay above the
95% CI after adjustment for case mix.
Concordance between preferred and actual decision-making
preferences was assessed using Kappa and association between
treatment, patient characteristics and decision-making style were
identified using Chi-squared tests. Statistical significance was taken
at p< 0.05.
Logistic regressions and multiple imputations were performed
using the open source statistical programming language R (version
3.0.1), with the remaining data handling and analysis performed in
Microsoft Excel for Windows 10.
Results
Baseline characteristics
A total of 3369 women with primary operable breast cancer
were recruited to the study between February 1, 2013 and June 6,
2018. Of these, 60 patients received treatment that was not obvi-
ously primary surgery or PET or had inadequate recorded data to
make an assessment on their treatment and were excluded from
the analysis. A further 455 were excluded from the analysis due to
having ER negative tumours or having insufficient data to draw
conclusions about their ER status. The final population for analysis
included 2854 patients with ER þ tumours, of whom 2354 were
treated with Surgery and 500 treated with PET. See Fig. 1 for study
flow diagram.
The median age of surgical patients in the study was 76 years
(range 70e95) and 84 years (70e102) for the PET patients. Baseline
patient and tumour characteristics are shown in Supplemental
Table ST3.
Associations with treatment type
Table 4 shows the results of the multivariable logistic regression
used in the adjustment model.
Poorer performance status as assessed by the ECOG PS tool was
associated with lower rates of surgical treatment. Higher rates of
co-morbidity (as assessed by the CCI) and functional status (as
assessed by ADL and IADL) were associated with lower rates of
surgical treatment. Larger tumour size was associated with lower
surgery rates, whereas patients with grade 2 or 3 tumours were3
more likely to undergo surgery compared to those with grade 1
disease.Rates of surgical treatment
The unadjusted rates of surgery varied substantially between
the 56 hospitals (Fig. 2(a)) ranging from 28.6% to 100%, with 6 of 56
(10.7%) falling outside the outer 99% limits and 23 of 56 (41.1%)
falling outside the inner 95% confidence limits on the funnel plots.
Table 4
Multivariate logistic regression results (N¼ 2854).
OR of having surgery 95% Confidence Intervals P value
Age (per year above 70) 0.866 0.847e0.886 <0.001
ECOG PS 1* compared to PS 0 0.556 0.411e0.751 <0.001
ECOG PS 2* compared to PS 0 0.340 0.202e0.572 <0.001
ECOG PS 3* compared to PS 0 0.338 0.153e0.745 0.007
ECOG PS 4* compared to PS 0 0.294 0.023e3.699 0.343
IADL (per increase in score) 1.236 1.086e1.405 0.001
CCI (per increase in score) 0.824 0.758e0.892 <0.001
ADL (per increase in score) 1.087 0.992e1.191 0.072
Size (per mm) 0.988 0.979e0.997 0.007
Grade 2 (compared to Grade 1) 1.453 1.057e1.998 0.022
Grade 3 (compared to Grade 1) 2.607 1.665e4.081 <0.001
*ECOG Performance Status 0: Fully active; ECOG Performance Status 1: Restricted in physically strenuous activities; ECOG Performance Status 2: Ambulatory and capable of all
self-care; ECOG Performance Status 3: Capable of only limited self-care; ECOG Performance Status 4: Completely Disabled; OR ¼ Odds Ratio; CI ¼ Confidence Interval
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5% respectively. Of the 23 outlying units, 10 had a higher than ex-
pected rate of surgery and 13 had a lower than expected rate of
surgery (i.e. a higher rate of PET).
Taking account of patient level characteristics and adjusting for
casemix (including patient age, ECOG performance status, Charlson
Comorbidity Index, Activities of Daily Living, Instrumental Activ-
ities of Daily Living, tumour size, tumour grade) reduced, but did
not eliminate, the variation in surgery rates between hospitals,
with 5 of 56 (8.9%) still falling outside the 99% confidence limits and
10 of 56 (17.9%) falling outside the 95% limits on the funnel plot
(Fig. 2(b)). Of the 10 persistently outlying units at the 95% level, 2
had a higher than expected rate of surgery and 8 had a lower than
expected rate of surgery (i.e. a higher rate of PET).Analysis of decision making styles
Of the study population, 2485/2854 (87.1%) patients had data
available to analyse on decision-making preference, 2097 of these
(84.4%) underwent surgery and 388 (15.6%) were treated with PET.
Patients preferred a doctor-centred decision-making style in 912
(36.7%), a shared decision-making style in 935 (37.6%) and a
patient-centred decision-making style in 638 (25.7%). Patients
rated their actual decision-making style as doctor-centred in 980
(39.4%), shared in 737 (29.7%) and patient-centred in 768 (30.9%).
Agreement between preferred and actual decision-making style
was 73.6% (Kappa¼ 0.60, p< 0.001; see Fig. 3).
Both preferred and actual decision-making styles were associ-
ated with final treatment type (see Table 5).
Patients treatedwith PET had significantlymore patient-centred
treatment decisions (42.3%) compared to shared (29.9%) or doctor-
centred (27.8%); p< 0.001. Whereas patients who underwent sur-
gery were more likely to have a doctor-centred (41.6%) treatment
decision as opposed to shared (29.6%) or patient-centred (28.8%);
p< 0.001 (Table 5).
Older patients had a significantly higher preference for patient-
centred decision making than younger patients and this was also
reflected in the actual decision type, with the youngest cohort
having much more doctor-centred treatment decisions (see
Table 6).
Units that had a high rate of surgery (i.e. a rate higher than the
upper 95% confidence limit), after adjustment for case mix, had
significantly higher rates of doctor-centred actual decision-making
styles (64.5% vs 30.6%; p< 0.001). Conversely, units with a low rate
of surgery (i.e. a rate less than the lower 95% confidence limit)
following adjustment for case mix, had significantly higher rates of
patient-centred actual decision-making style (35.2% vs 11.8%;
p< 0.001) (see Table 7).4
Discussion
In this large prospective cohort study of the treatment of older
women breast cancer across 56 units in England, 17.5% (500/2854)
of ER þ patients were treated with PET, which is lower than figures
published by similar recent audits; most recently, the National
Audit of Breast Cancer in Older Patients found that 24% of women
aged 70þ years with early ERþ breast cancer were treatedwith PET
between 2014 and 2017 [12]. This may be because our study missed
recruitment of some of the older, frailer cohort that would be more
like to be treated in this way due to the requirement for consented
enrolment. Comparison of the study data with UK national registry
data age distribution in older cancer patients does show that this
study slightly over recruited younger women (70e75) and under
recruited older women, so the results may not be wholly repre-
sentative of the picture across the UK [34].
The analysis demonstrates that increasing age at diagnosis is
associatedwith a reduced likelihood of receiving surgical treatment
which is consistent with other similar studies [1,15,35e38]. Higher
levels of comorbidity and functional impairment (using ADL, IADL
and ECOG performance status) were also associated with non-
surgical treatment, which is again consistent with other pub-
lished studies, where co-morbidity is often stated as a major reason
for choosing PET over surgery [14,39,40]. Tumour factors were also
associated with treatment type, with larger tumours being less
likely to be treated surgically which may represent patients and
clinicians trying to avoid more major surgery, such as mastectomy
and axillary node clearance. These results corroborate and update
those found by our group in a registry study of 17 129 women aged
70 years and over between 2002 and 2010 [13].
There was considerable variation in the rates of surgical treat-
ment across the 56 hospitals and, whilst this improved with case-
mix adjustment, there was still considerable variation, with 17.9%
of units remaining outside the 95% limits in funnel plot analysis.
Two hospitals had significantly higher and eight hospitals had
significantly lower rates of surgery than could be explained by the
case mix information available.
This persistence of variation in the treatment of older women
with operable, ER þ breast cancer at hospital level is due to factors
not included in the case-mix adjustment. One possible cause is
clinician or patient preference for either treatment. These results
clearly show that in units with higher rates of surgery, there was a
significantly higher proportion of doctor-led decision-making
styles and conversely, in units with higher rates of PET there were
significantly more patient-led decision-making styles.
Treatment received was strongly correlated with decision-
making style, with patients choosing PET having a higher rate of
patient-centred decision-making styles compared to those treated
Fig. 2. a) Unadjusted and b) adjusted rates of surgery across 56 UK breast units.
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Fig. 3. Concordance between patients' preferred and actual decision-making styles.
Table 5
Patients’ preferred and actual decision type according to treatment received.
Preferred decision type Surgery (n¼ 2097) PET (n¼ 388) p Actual decision type Surgery (n¼ 2097) PET (n¼ 388) P
Doctor-centred 800 112 <0.001 Doctor-centred 872 108 <0.001
38.1% 28.9% 41.6% 27.8%
Shared 802 133 Shared 621 116
38.2% 34.3% 29.6% 29.9%
Patient-centred 495 143 Patient-centred 604 164
23.6% 36.9% 28.8% 42.3%
Table 6
Patients preferred and actual decision type by age category.
Age 70-74 (n¼ 940) 75-79 (n¼ 734) 80-84 (n¼ 479) 85þ (n ¼ 332) p-value
Preferred decision type
Doctor-centred 358 (38.1%) 299 (40.7%) 163 (34.0%) 92 (27.7%) <0.001
Shared 383 (40.7%) 267 (36.4%) 163 (34.0%) 122 (36.7%)
Patient-centred 199 (21.2%) 168 (22.9%) 153 (31.9%) 118 (35.5%)
Actual decision type
Doctor-centred 418 (44.5%) 324 (44.1%) 154 (32.2%) 84 (25.3%) <0.001
Shared 287 (30.5%) 194 (26.4%) 144 (30.1%) 112 (33.7%)
Patient-centred 235 (25.0%) 216 (29.4%) 181 (37.8%) 136 (41.0%)
Table 7
Patients actual decision-making style by hospital surgery rate.
Low Surgery Rate (n¼ 216) Average Surgery Rate (n¼ 2100) High Surgery Rate (n¼ 169) p-value
Doctor-centred 66 (30.6%) 805 (38.3%) 109 (64.5%) <0.001
Shared 74 (34.3%) 623 (29.7%) 40 (23.7%)
Patient-centred 76 (35.2%) 672 (32.0%) 20 (11.8%)
J.L. Morgan, G. Holmes, S. Ward et al. European Journal of Surgical Oncology xxx (xxxx) xxxsurgically. This suggests that a significant proportion of women are
choosing PET as a means of avoiding surgery. It also implies that
those units with high surgery rates may be more strongly pro-
moting surgery and not taking due consideration of the preferences
of women themselves.What is interesting is that a UK survey found
that most breast healthcare professionals had a strong view that, if
given the choice between surgery and PET, most patients would
favour surgery [41], which is not what our results would suggest.
Indeed, patient preference for or refusal of surgery is also often
stated a reason for treatment with PET [42], however Lavelle and
colleagues found, in their cohort of 800 women over the age of 70,
that lower rates of surgery among elderly patients are unlikely to be
due to patient choice [15]. Instead the observed variation may
reflect clinician preference and how or whether alternative6
treatment options, such as PET, are presented at all, as was pro-
posed by Hamaker and colleagues [43]. Current guidelines on the
use of PET in the older breast cancer population state it should only
be used in patients with a short life expectancy (less than 2e3
years), or when significant comorbidities preclude surgery, or in
patients who refuse surgery [44,45]. It is left to the treating clini-
cians’ judgement as to which patients should be offered PET as an
alternative treatment option to surgery. Comprehensive geriatric
assessment may have a role here to help clinicians identify the
patients more to benefit from being offered a choice and to support
communication with patients [46].
Qualitative research in this older group of patients has sug-
gested that they are more passive decision-makers, relying on the
advice of healthcare professionals [20,21,47]. However these results
J.L. Morgan, G. Holmes, S. Ward et al. European Journal of Surgical Oncology xxx (xxxx) xxxclearly show there are a significant proportion of older womenwho
prefer a shared or patient-centred decision-making style, in
particular in the oldest groups. Previous studies have examined the
concordance between healthcare professional and patient prefer-
ence for decision-making in breast cancer patients and found that
their perceptions were often inconsistent with patient preference
[19]. Within this study, around three quarters of patients achieved
their decision-making style, although this means a quarter did not,
raising the possibility that they may be making choices which are
not concordant with their treatment preferences. One of the factors
which patients may prioritise highly in this age group is quality-of-
life [48] and the maintenance of independence [20], both of which
may be more highly preserved with PET than surgery [9], but
valued less by clinicians who may innately prioritise survival
metrics. In younger women the values of patients and clinicians are
likely to be concordant but less so in older women. This may ac-
count for some of the discordancy observed in this study. There is
also a possibility that some clinicians taking partmay have adjusted
their approach to information-giving in the study due to an
awareness that information on decision-making was being
collected.
Increasing age was associated with more patient-centred deci-
sion-making styles, both preferred and actual, which may partially
explain the higher rates of PET in the oldest old. This may however
be confounded by surgeons feeling more inclined to stress the
importance of surgery in the youngest cohort, resulting in a
perceived doctor-centred decision by patients in the younger
group. Clinicians may also be aware that in the oldest and frailest
women, treatment is unlikely to have a huge impact on survival as
the majority of these women will die of non-breast cancer causes,
so choice has less impact on survival.
This study has allowed us to collect large amounts of complex
patient, tumour and treatment data on women with operable
breast cancer from across the UK. Additionally, there were some
issues with data completeness, with cognition and HER2 status
subject to the most missing data. The well-established practice of
imputation of data has therefore been used where it was deemed
appropriate [49].
This study has identified outlying practice. This is important
because patients who are treated with PET have been shown to
have poorer outcomes compared to those treated with surgery
[22,50e53] but also overtreatment of frail older women who are
unlikely to die of breast cancer regardless of treatment type may
suffer unnecessary harms. Continuation of this variability in prac-
tice may result in a post-code lottery and further guidelines on the
management of older women with operable breast cancer are
needed. Having said that, these results do support the reports that
some of the use of PET in the older breast cancer populationmay be
due to patient choice which must be respected provided appro-
priate information is provided to patients to make an informed
choice. There is evidence to suggest that older patients may pri-
oritise quality-of-life over quantity [47,54], and clinicians should
take this into account when counselling patients about treatment
options. Shared decision-making suggests that patients should be
informed of their treatment options [17] and for some older women
it may be appropriate to offer PET as an alternative to ‘standard’
surgical treatment and allow the patient to decide what is best for
them. Previous work by our group supports an individualised
approach to treatment decision-making in this group [55] and
consequently, we have recently developed, validated and trialled a
decision aid to support decision making for older women facing the
choice of surgery or PET [56e59]. This tool is available on line at
https://agegap.shef.ac.uk/. The tool displays health, age and fitness
stratified survival outcomes for women over age 70 with early
breast cancer according to whether they have surgery or PET. We7
hope to adapt this in the near future by adding stratified quality-of
life and functional outcomes from treatment to ensure women get
the information they need and value whenmaking this choice. This
may enable better evidence-based individualised decision-making
and reduce variation.
Funding
This paper presents independent research funded by the Na-
tional Institute for Health Research (NIHR) under its Programme
Grants for Applied Research Programme (Grant Reference Number
RP-PG-1209-10071). The views expressed are those of the authors
and not necessarily those of the NIHR or the Department of Health
and Social Care.
Previous communication to a society or meeting: Some data
were submitted and accepted for presentation to European Breast
Cancer Conference March 2020 (Barcelona) and Association of
Breast Surgery Conference June 2020 (Bournemouth), although
both conferences were subsequently cancelled due to the COVID-19
pandemic.
Disclosures
The authors declare no conflict of interest. Professor Stephen
Walters is a National Institute for Health Research (NIHR) Senior
Investigator and Jenna Morgan is a NIHR Clinical Lecturer.
Appendix A. Supplementary data
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.ejso.2020.09.029.
References
[1] Lavelle K, Moran A, Howell A, Bundred N, Campbell M, Todd C. Older women
with operable breast cancer are less likely to have surgery. Br J Surg
2007;94(10):1209e15.
[2] Wyld L, Garg DK, Kumar ID, Brown H, Reed MW. Stage and treatment varia-
tion with age in postmenopausal women with breast cancer: compliance with
guidelines. Br J Canc 2004;90(8):1486e91.
[3] Derks MGM, Bastiaannet E, Kiderlen M, Hilling DE, Boelens PG, Walsh PM,
et al. Variation in treatment and survival of older patients with non-metastatic
breast cancer in five European countries: a population-based cohort study
from the EURECCA Breast Cancer Group. Br J Canc 2018;119(1):121e9.
[4] Jauhari YGMMJ, Cromwell D, Horgan K, Dodwell D. National audit of breast
cancer in older patients annual report. Healthcare Quality Improvement
Partnership; 2018.
[5] Morgan J, Wyld L, Collins K, Reed M. Surgery versus primary endocrine
therapy for operable primary breast cancer in elderly women (70 years plus).
Cochrane Database Syst Rev 2014;5:CD004272.
[6] Chakrabarti J, Kenny F, Syed B, Robertson J, Blamey R, Cheung K. A randomised
trial of mastectomy only versus tamoxifen for treating elderly patients with
operable primary breast cancer-Final results at 20-year follow-up. Crit Rev
Oncol-Hematol 2011;78(3):260e4.
[7] Biganzoli L, Wildiers H, Oakman C, Marotti L, Loibl S, Kunkler I, et al. Man-
agement of elderly patients with breast cancer: updated recommendations of
the international society of geriatric Oncology (SIOG) and European society of
breast cancer specialists (EUSOMA). Lancet Oncol 2012;13(4):148e60.
[8] Gray R. Early breast cancer trialists' collaborative group analysis of surgery
versus PET unpublished data. 2019.
[9] Tang V, Zhao S, Boscardin J, Sudore R, Covinsky K, Walter LC, et al. Functional
status and survival after breast cancer surgery in nursing home residents.
JAMA Surg 2018 Dec 1;153:1090.
[10] Bates T, Evans T, Lagord C, Monypenny I, Kearins O, Lawrence G. A population
based study of variations in operation rates for breast cancer, of comorbidity
and prognosis at diagnosis: failure to operate for early breast cancer in older
women. Eur J Surg Oncol 2014;40(10):1230e6.
[11] BCCOM. Breast Cancer. Clinical Outcome Measures (BCCOM) Project: analysis
of the management of symptomatic breast cancers diagnosed in 2004. 2007.
3rd Year Report December 2007.
[12] Annual Report National audit of breast cancer in older patients. 2018.
accessed, https://associationofbreastsurgery.org.uk/media/64447/nabcop-
2018-annual-report.pdf. [Accessed 3 January 2019].
[13] Morgan JRP, Ward S, Francis M, Lawrence G, Collins K, Reed M, et al. Case mix
J.L. Morgan, G. Holmes, S. Ward et al. European Journal of Surgical Oncology xxx (xxxx) xxxdoes not fully explain variation in rates of non-surgical treatment of older
women with operable breast cancer. Br J Surg 2015;102(9):1056e63.
[14] Wylie S, Ravichandran D. A UK national survey of breast surgeons on primary
endocrine therapy of early operable breast cancer. Ann R Coll Surg Engl
2013;95:353e6.
[15] Lavelle K, Sowerbutts A, Bundred N, Pilling M, Degner L, Stockton C, et al. Is
lack of surgery for older breast cancer patients in the UK explained by patient
choice or poor health? A prospective cohort study. Br J Canc 2014;110:
573e83.
[16] Morgan JL, Walters SJ, Collins K, Robinson TG, Cheung KL, Audisio R, et al.
What influences healthcare professionals' treatment preferences for older
women with operable breast cancer? An application of the discrete choice
experiment. Eur J Surg Oncol 2017;43(7):1282e7.
[17] Coulter A, Collins A. Making shared decision-making a reality: No decision
about me, without me. London: The King’s Fund; 2011.
[18] Consent GMC. Patients and doctors making decisions together. London:
General Medical Council; 2008.
[19] Vogel BA, Helmes AW, Hasenburg A. Concordance between patients' desired
and actual decision-making roles in breast cancer care. Psycho Oncol
2008;17(2):182e9.
[20] Husain LS, Collins K, Reed M, Wyld L. Choices in cancer treatment: a quali-
tative study of the older women's (>70 years) perspective. Psycho Oncol
2008;17(4):410e6.
[21] Caldon L, Walters S, Reed M. Changing trends in the decision making pref-
erences of women with early breast cancer. Br J Surg 2008;95(3):312e8.
[22] Schonberg M, Marcantonio E, Li D, Silliman R, Ngo L, McCarthy E. Breast
cancer among the oldest old: tumor characteristics, treatment choices, and
survival. J Clin Oncol 2010;28(12):2038e45.
[23] von Elm E, Altman DG, Egger M, Pocock SL, Gøtzsche PC, Vandenbroucke JP,
et al. The Strengthening the Reporting of Observational Studies in Epidemi-
ology (STROBE) statement: guidelines for reporting observational studies.
Lancet 2007;370(9596):1453e7.
[24] Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying
prognostic comorbidity in longitudinal studies: development and validation.
J Chron Dis 1987;40:373e83.
[25] Mahoney F, Barthel D. Functional evaluation: the barthel index. Md State Med
J 1965 Feb;14:61e5.
[26] Lawton MP, Brody EM. Assessment of older people: self-maintaining and
instrumental activities of daily living. Gerontol 1969 Sep 1;9:179e86.
[27] Folstein MF, Folstein SE, McHugh PR. A practical method for grading the
cognitive state of patients for the clinician. J Psychiatr Res 1975:189e98.
"Mini-mental state".
[28] Vigano AL, di Tomasso J, Kilgour RD, Trutschnigg B, Lucar E, Morais JA, et al.
The abridged patient-generated subjective global assessment is a useful tool
for early detection and characterization of cancer cachexia. J Acad Nutr Diet
2014 Jul;114:1088e98.
[29] Strull W, Lo B, Charles G. Do patients want to participate in medical decision
making? J Am Med Assoc 1984;252:2990e4.
[30] Sutherland H, Llewellyn-Thomas H, Lockwood G, Tritchler D, Till J. Cancer
patients: their desire for information and participation in treatment decisions.
J R Soc Med 1989;82:260e3.
[31] Su Y-S, Yajima M, Gelman AE, Hill J. Multiple imputation with diagnostics (mi)
in R: opening Windows into the black box. J Stat Software 2011;45(2):1e31.
[32] Rubin D. Multiple imputation from non-response in surveys. New York: J
Wiley & Sons; 1987.
[33] Spiegelhalter D. Funnel plots for comparing institutional performance. Stat
Med 2005;24:1185e202.
[34] Todd A, Martin C, Morgan J, Herbert E, Burton M, Reed M, et al. Age specific
recruitment and retention to a large multicentre observational breast cancer
trial in older women: the Age Gap Trial. Submitted to Journal of Geriatric
Oncology 2020. unpublished data.
[35] Lavelle K, Todd C, Moran A, Howell A, Bundred N, Campbell M. Non-standard
management of breast cancer increases with age in the UK: a population
based cohort of women >¼ 65 years. Br J Canc 2007;96(8):1197e203.
[36] Ali A, Greenberg D, Wishart G, Pharoah P. Patient and tumour characteristics,
management, and age-specific survival in women with breast cancer in the
East of England. Br J Canc 2011;104(4):564e70.
[37] Van de Water W, Markopoulos C, van de Velde C, Seynaeve C, Hasenburg A,
Rea D, et al. Association between age at diagnosis and disease-specific mor-
tality among postmenopausal women with hormone receptor-positive breast
cancer. J Am Med Assoc 2012;307(6):590e7.8
[38] Bastiaannet E, Liefers G, de Craen A, Kuppen P, van de Water W, Portielje J-E,
et al. Breast cancer in elderly compared to younger patients in The
Netherlands: stage at diagnosis, treatment and survival in 127,805 unselected
patients. Breast Canc Res Treat 2010;124:801e7.
[39] Balakrishnan A, Ravichandran D. Early operable breast cancer in elderly
women treated with an aromatase inhibitor letrozole as sole therapy. Br J
Canc 2011;105(12):1825e9.
[40] Rao V, Jameel J, Mahapatra T, McManus P, Fox J, Drew P. Surgery is associated
with lower morbidity and longer survival in elderly breast cancer patients
over 80. Breast J 2007;13(4):368e73.
[41] Morgan JL, Collins K, Robinson TG, Cheung KL, Audisio R, Reed MW, et al.
Healthcare professionals' preferences for surgery or primary endocrine ther-
apy to treat older women with operable breast cancer. Eur J Surg Oncol
2015;41(9):1234e42.
[42] Wink C, al e. Hormone treatment without surgery for patients aged 75 years
or older with operable breast cancer. Ann Surg Oncol 2012;19:1185e91.
[43] Hamaker M, Bastiaannet E, Evers D, Van de Water W, Smorenburg C,
Maartense E, et al. Omission of surgery in elderly patients with early stage
breast cancer. Eur J Canc 2013;49:545e52.
[44] NICE. CG80 Early and locally advanced breast cancer: full guideline. 2009.
accessed, http://www.nice.org.uk/nicemedia/live/12132/43413/43413.pdf.
[Accessed 7 May 2020].
[45] Audisio R, Pope D, Ramesh H, Gennari R, van Leeuwen B, West Cea. Shall we
operate? Preoperative assessment in elderly cancer patients (PACE) can help.
A SIOG surgical task force prospective study. Crit Rev Oncol Hematol
2008;65(2):156e63.
[46] Mohile SG, Epstein RM, Hurria A, Heckler CE, Canin B, Culacova E, et al.
Communication with older patients with cancer using geriatric assessment: a
cluster-randomized clinical trial from the National Cancer Institute Commu-
nity Oncology Research Program. JAMA Oncology 2020;6(2):196e204.
[47] Ekdahl A, Andersson L, Friedrichsen M. They do what they think is the best for
me: frail elderly patients' preferences for participation in their care during
hospitalization. Patient Education and Counselling 2010;80:233e40.
[48] Shrestha A, Martin C, Burton M, Walters S, Collins K, Wyld L. Quality of life
versus length of life considerations in cancer patients: a systematic literature
review. Psycho Oncol 2019;28:1367e80.
[49] Buuren Sv, Groothuis-Oudshoorn K. MICE: multivariate imputation by
chained equations in R. J Stat Software 2011;45(3):1e67.
[50] Van Leeuwen B, Rosenkranz K, Feng L, Bedrosian I, Hartmann K, Hunt K, et al.
The effect of under-treatment of breast cancer in women 80 years of age and
older. Crit Rev Oncol Hematol 2011;79:315e20.
[51] Bouchardy C, Rapiti E, Fioretta G, Laissue P, Neyroud-Caspar I, Schafer P, et al.
Undertreatment strongly decreases prognosis of breast cancer in elderly
women. J Clin Oncol 2003;21(19):3580e7.
[52] Bastiaannet E, Portielje J, van de Velde C, de Craen A, van der Velde S,
Kuppen P, et al. Lack of survival gain for elderly women with breast cancer.
Oncol 2011;16(4):415e23.
[53] Wishart G, Greenberg D, Chou P, Brown C, Duffy S, Puroshotham A. Treatment
and survival in breast cancer in the eastern region of England. Ann Oncol
2010;21(2):291e6.
[54] Meropol NJ, Egleston BL, Buzaglo JS, Benson 3rd AB, Cegala DJ, Diefenbach MA,
et al. Cancer patient preferences for quality and length of life. Cancer
2008;113(12):3459e66.
[55] Morgan J, Burton M, Collins K, Lifford KJ, Robinson TG, Cheung KL, et al. Psycho
Oncol 2015;24:1761e6.
[56] Ward SE, Richards PD, Morgan JL, Holmes GR, Broggio JW, Collins K, et al.
Omission of surgery in older women with early breast cancer has an adverse
impact on breast cancer-specific survival. BJS 2018;105:1454e63.
[57] Lifford Kate J, Edwards Adrian, Burton Maria, Harder Helena, Armitage Fiona,
Morgan Jenna L, Caldon Lisa, , Kirsty Balachandran Alistair Ring Karen Collins
Malcolm Reed Lynda Wyld, Kate Brain. Efficient development and usability
testing of decision support interventions for older women with breast cancer.
Patient Prefer Adherence 2019;13:131e43.
[58] Burton M, Collins KA, Lifford KJ, Brain K, Wyld L, Caldon L, et al. The infor-
mation and decision support needs of older women (>75 yrs) facing treat-
ment choices for breast cancer: a qualitative study. Psycho Oncol 2015
Aug;24(8):878e84.
[59] Holmes G, Ward S, Morgan JL, Broggio JW, Collins K, Richards P, et al. Bridging
the Age Gap A new prognostic model that predicts survival and aids in pri-
mary treatment decisions for older women with ER-positive early breast
cancer. BJS 2020. in press.
